Medicina de precisión en cáncer colorrectal y gastroesofágico avanzado

Arnold, 2020, Global Burden of 5 Major Types of Gastrointestinal Cancer, Gastroenterology., 159, 335, 10.1053/j.gastro.2020.02.068 Thirion, 2004, Meta-Analysis Group in Cancer. Modulation of fluorouracil by leucovorin in patients with advanced colorectal cancer: an updated meta-analysis, J Clin Oncol., 22, 3766, 10.1200/JCO.2004.03.104 Meta-analysis Group In Cancer, 1998, Efficacy of intravenous continuous infusion of fluorouracil compared with bolus administration in advanced colorectal cancer, J Clin Oncol., 16, 301, 10.1200/JCO.1998.16.1.301 Cunningham, 1998, Randomised trial of irinotecan plus supportive care versus supportive care alone after fluorouracil failure for patients with metastatic colorectal cancer, Lancet., 352, 1413, 10.1016/S0140-6736(98)02309-5 Rougier, 1998, Randomised trial of irinotecan versus fluorouracil by continuous infusion after fluorouracil failure in patients with metastatic colorectal cancer, Lancet., 352, 1407, 10.1016/S0140-6736(98)03085-2 Wiseman, 1999, Oxaliplatin: a review of its use in the management of metastatic colorectal cancer, Drugs Aging., 14, 459, 10.2165/00002512-199914060-00006 Lévi, 1992, A chronopharmacologic phase II clinical trial with 5-fluorouracil, folinic acid, and oxaliplatin using an ambulatory multichannel programmable pump. High antitumor effectiveness against metastatic colorectal cancer, Cancer., 69, 893, 10.1002/1097-0142(19920215)69:4<893::AID-CNCR2820690410>3.0.CO;2-X de Gramont, 2000, Leucovorin and fluorouracil with or without oxaliplatin as first-line treatment in advanced colorectal cancer, J Clin Oncol., 18, 2938, 10.1200/JCO.2000.18.16.2938 Douillard, 2000, Irinotecan combined with fluorouracil compared with fluorouracil alone as first-line treatment for metastatic colorectal cancer: a multicentre randomised trial, Lancet., 355, 1041, 10.1016/S0140-6736(00)02034-1 Falcone, 2007, J Clin Oncol., 25, 1670, 10.1200/JCO.2006.09.0928 Salomon, 1995, Epidermal growth factor-related peptides and their receptors in human malignancies, Crit Rev Oncol Hematol., 19, 183, 10.1016/1040-8428(94)00144-I Klapper, 2000, Biochemical and clinical implications of the ErbB/HER signaling network of growth factor receptors, Adv Cancer Res., 77, 25, 10.1016/S0065-230X(08)60784-8 Cunningham, 2004, Cetuximab monotherapy and cetuximab plus irinotecan in irinotecan-refractory metastatic colorectal cancer, N Engl J Med., 351, 337, 10.1056/NEJMoa033025 Van Cutsem, 2009, Cetuximab and chemotherapy as initial treatment for metastatic colorectal cancer, N Engl J Med., 360, 1408, 10.1056/NEJMoa0805019 De Roock, 2008, KRAS wild-type state predicts survival and is associated to early radiological response in metastatic colorectal cancer treated with cetuximab, Ann Oncol., 19, 508, 10.1093/annonc/mdm496 Amado, 2008, Wild-type KRAS is required for panitumumab efficacy in patients with metastatic colorectal cancer, J Clin Oncol., 26, 1626, 10.1200/JCO.2007.14.7116 Benvenuti, 2007, Oncogenic activation of the RAS/RAF signaling pathway impairs the response of metastatic colorectal cancers to anti-epidermal growth factor receptor antibody therapies, Cancer Res., 67, 2643, 10.1158/0008-5472.CAN-06-4158 Garcia, 2020, Bevacizumab (Avastin®) in cancer treatment: A review of 15 years of clinical experience and future outlook, Cancer Treat Rev., 86, 102017, 10.1016/j.ctrv.2020.102017 Venook, 2017, Effect of First-Line Chemotherapy Combined With Cetuximab or Bevacizumab on Overall Survival in Patients With KRAS Wild-Type Advanced or Metastatic Colorectal Cancer: A Randomized Clinical Trial, JAMA., 317, 2392, 10.1001/jama.2017.7105 NIH. Cancer Stat Facts: Colorectal Cancer. (consultado septiembre de 2021). Disponible en: https://seer.cancer.gov/statfacts/html/colorect.html. Morad, 2021, Hallmarks of response, resistance, and toxicity to immune checkpoint blockade, Cell., 184, 5309, 10.1016/j.cell.2021.09.020 Topalian, 2015, Immune checkpoint blockade: a common denominator approach to cancer therapy, Cancer Cell., 27, 450, 10.1016/j.ccell.2015.03.001 Gong, 2018, Development of PD-1 and PD-L1 inhibitors as a form of cancer immunotherapy: a comprehensive review of registration trials and future considerations, J Immunother Cancer., 6, 8, 10.1186/s40425-018-0316-z Germano, 2018, The Clinical Impact of the Genomic Landscape of Mismatch Repair-Deficient Cancers, Cancer Discov., 8, 1518, 10.1158/2159-8290.CD-18-0150 Lichtenstern, 2020, Immunotherapy, Inflammation and Colorectal Cancer. Cells., 9, 618 Larrea, 2010, SnapShot: DNA mismatch repair, Cell., 141, 730, 10.1016/j.cell.2010.05.002 Liebl, 2019, Identification of responders to immune checkpoint therapy: which biomarkers have the highest value?, J Eur Acad Dermatol Venereol., 33, 52, 10.1111/jdv.15992 Kulangara, 2019, Clinical Utility of the Combined Positive Score for Programmed Death Ligand-1 Expression and the Approval of Pembrolizumab for Treatment of Gastric Cancer, Arch Pathol Lab Med., 143, 330, 10.5858/arpa.2018-0043-OA Le, 2017, Mismatch repair deficiency predicts response of solid tumors to PD-1 blockade, Science., 357, 409, 10.1126/science.aan6733 Le, 2015, PD-1 Blockade in Tumors with Mismatch-Repair Deficiency, N Engl J Med., 372, 2509, 10.1056/NEJMoa1500596 O’Neil, 2017, Safety and antitumor activity of the anti-PD-1 antibody pembrolizumab in patients with advanced colorectal carcinoma, PLoS One., 12, e0189848, 10.1371/journal.pone.0189848 Lenz, 2022, First-Line Nivolumab Plus Low-Dose Ipilimumab for Microsatellite Instability-High/Mismatch Repair-Deficient Metastatic Colorectal Cancer: The Phase II CheckMate 142 Study, J Clin Oncol., 40, 161, 10.1200/JCO.21.01015 Azad, 2020, Nivolumab Is Effective in Mismatch Repair-Deficient Noncolorectal Cancers: Results From Arm Z1D-A Subprotocol of the NCI-MATCH (EAY131) Study, J Clin Oncol., 38, 214, 10.1200/JCO.19.00818 Overman, 2017, Nivolumab in patients with metastatic DNA mismatch repair-deficient or microsatellite instability-high colorectal cancer (CheckMate 142): an open-label, multicentre, phase 2 study, Lancet Oncol., 18, 1182, 10.1016/S1470-2045(17)30422-9 André, 2020, KEYNOTE-177 Investigators. Pembrolizumab in Microsatellite-Instability-High Advanced Colorectal Cancer, N Engl J Med, 383, 2207, 10.1056/NEJMoa2017699 Chalabi, 2020, Neoadjuvant immunotherapy leads to pathological responses in MMR-proficient and MMR-deficient early-stage colon cancers, Nat Med., 26, 566, 10.1038/s41591-020-0805-8 Schirripa, 2015, BRAF and RAS mutations as prognostic factors in metastatic colorectal cancer patients undergoing liver resection, Br J Cancer., 112, 1921, 10.1038/bjc.2015.142 Cremolini, 2015, FOLFOXIRI plus bevacizumab versus FOLFIRI plus bevacizumab as first-line treatment of patients with metastatic colorectal cancer: updated overall survival and molecular subgroup analyses of the open-label, phase 3 TRIBE study, Lancet Oncol., 16, 1306, 10.1016/S1470-2045(15)00122-9 Seligmann, 2017, Investigating the poor outcomes of BRAF-mutant advanced colorectal cancer: analysis from 2530 patients in randomised clinical trials, Ann Oncol., 28, 562, 10.1093/annonc/mdw645 Morris, 2014, Progression-free survival remains poor over sequential lines of systemic therapy in patients with BRAF-mutated colorectal cancer, Clin Colorectal Cancer., 13, 164, 10.1016/j.clcc.2014.06.001 Seymour, 2013, Panitumumab and irinotecan versus irinotecan alone for patients with KRAS wild-type, fluorouracil-resistant advanced colorectal cancer (PICCOLO): a prospectively stratified randomised trial, Lancet Oncol., 14, 749, 10.1016/S1470-2045(13)70163-3 Peeters, 2015, Analysis of KRAS/NRAS Mutations in a Phase III Study of Panitumumab with FOLFIRI Compared with FOLFIRI Alone as Second-line Treatment for Metastatic Colorectal Cancer, Clin Cancer Res., 21, 5469, 10.1158/1078-0432.CCR-15-0526 Flaherty, 2010, Inhibition of mutated, activated BRAF in metastatic melanoma, N Engl J Med., 363, 809, 10.1056/NEJMoa1002011 Corcoran, 2018, Combined BRAF. EGFR, and MEK Inhibition in Patients with BRAF V600E-Mutant Colorectal Cancer, Cancer Discov., 8, 428, 10.1158/2159-8290.CD-17-1226 Van Cutsem, 2019, Binimetinib. Encorafenib, and Cetuximab Triplet Therapy for Patients With BRAF V600E-Mutant Metastatic Colorectal Cancer: Safety Lead-In Results From the Phase III BEACON Colorectal Cancer Study, J Clin Oncol., 37, 1460, 10.1200/JCO.18.02459 Kopetz, 2019, Encorafenib. Binimetinib, and Cetuximab in BRAF V600E-Mutated Colorectal Cancer, N Engl J Med., 381, 1632, 10.1056/NEJMoa1908075 Sartore-Bianchi, 2016, Dual-targeted therapy with trastuzumab and lapatinib in treatment-refractory, KRAS codon 12/13 wild-type. HER2-positive metastatic colorectal cancer (HERACLES): a proof-of-concept, multicentre, open-label, phase 2 trial, Lancet Oncol., 17, 738, 10.1016/S1470-2045(16)00150-9 Meric-Bernstam, 2019, Pertuzumab plus trastuzumab for HER2-amplified metastatic colorectal cancer (MyPathway): an updated report from a multicentre, open-label, phase 2a, multiple basket study, Lancet Oncol., 20, 518, 10.1016/S1470-2045(18)30904-5 Sartore-Bianchi, 2020, Pertuzumab and trastuzumab emtansine in patients with HER2-amplified metastatic colorectal cancer: the phase II HERACLES-B trial, ESMO Open., 5, e000911, 10.1136/esmoopen-2020-000911 Siena, 2021, DESTINY-CRC01 investigators. Trastuzumab deruxtecan (DS-8201) in patients with HER2-expressing metastatic colorectal cancer (DESTINY-CRC01): a multicentre, open-label, phase 2 trial, Lancet Oncol., 22, 779, 10.1016/S1470-2045(21)00086-3 Yoshino, 2021, Trastuzumab deruxtecan (T-DXd; DS-8201) in patients (pts) with HER2-expressing metastatic colorectal cancer (mCRC): Final results from a phase 2, multicenter, open-label study (DESTINY-CRC01), J Clin Oncol., 39 Siena, 2021, Exploratory Biomarker Analysis of DESTINYCRC01, a Phase 2, Multicenter, Open-Label Study of Trastuzumab Deruxtecan (T-DXd, DS-8201) in Patients With HER2-Expressing Metastatic Colorectal Cancer, Ann. Oncol., 32, S530 Neumann, 2009, Frequency and type of KRAS mutations in routine diagnostic analysis of metastatic colorectal cancer, Pathol Res Pract., 205, 858, 10.1016/j.prp.2009.07.010 Henry, 2021, Comprehensive Clinical and Molecular Characterization of KRASG12C-Mutant Colorectal Cancer, JCO Precis Oncol., 5 Di Nicolantonio, 2021, Precision oncology in metastatic colorectal cancer - from biology to medicine, Nat Rev Clin Oncol., 18, 506, 10.1038/s41571-021-00495-z Fakih, 2020, CodeBreak 100: Activity of AMG 510, a novel small molecule inhibitor of KRAS G12C, in patients with advanced colorectal cancer, J Clin Oncol., 38 Weiss, 2021, KRYSTAL-1: Adagrasib (MRTX849) as monotherapy or combined with cetuximab (Cetux) in patients (Pts) with colorectal cancer (CRC) harboring a KRAS G12C mutation, Annals of Oncology., 32, S1283 Do, 2013, Wee1 kinase as a target for cancer therapy, Cell Cycle., 12, 3159, 10.4161/cc.26062 Seligmann, 2021, FOCUS4 Trial Investigators. Inhibition of WEE1 Is Effective in TP53- and RAS-Mutant Metastatic Colorectal Cancer: A Randomized Trial (FOCUS4-C) Comparing Adavosertib (AZD1775) With Active Monitoring, J Clin Oncol., 39, 3705, 10.1200/JCO.21.01435 Ebinger, 2016, Modest overall survival improvements from 1998 to 2009 in metastatic gastric cancer patients: a population-based SEER analysis, Gastric Cancer., 19, 723, 10.1007/s10120-015-0541-9 Cunningham, 2008, Upper Gastrointestinal Clinical Studies Group of the National Cancer Research Institute of the United Kingdom. Capecitabine and oxaliplatin for advanced esophagogastric cancer, N Engl J Med., 358, 36, 10.1056/NEJMoa073149 Al-Batran, 2019, Lancet, 393, 1948, 10.1016/S0140-6736(18)32557-1 Pectasides, 2018, Genomic Heterogeneity as a Barrier to Precision Medicine in Gastroesophageal Adenocarcinoma, Cancer Discov., 8, 37, 10.1158/2159-8290.CD-17-0395 Cancer, 2014, Genome Atlas Research Network. Comprehensive molecular characterization of gastric adenocarcinoma, Nature., 513, 202, 10.1038/nature13480 Ichikawa, 2017, Actionable gene-based classification toward precision medicine in gastric cancer, Genome Med., 9, 93, 10.1186/s13073-017-0484-3 Bang, 2010, ToGA Trial Investigators. Trastuzumab in combination with chemotherapy versus chemotherapy alone for treatment of HER2-positive advanced gastric or gastro-oesophageal junction cancer (ToGA): a phase 3, open-label, randomised controlled trial, Lancet., 376, 687, 10.1016/S0140-6736(10)61121-X Van Cutsem, 2015, HER2 screening data from ToGA: targeting HER2 in gastric and gastroesophageal junction cancer, Gastric Cancer., 18, 476, 10.1007/s10120-014-0402-y Hecht, 2016, Lapatinib in Combination With Capecitabine Plus Oxaliplatin in Human Epidermal Growth Factor Receptor 2-Positive Advanced or Metastatic Gastric. Esophageal, or Gastroesophageal Adenocarcinoma: TRIO-013/LOGiC--A Randomized Phase III Trial, J Clin Oncol., 34, 443, 10.1200/JCO.2015.62.6598 Satoh, 2014, Lapatinib plus paclitaxel versus paclitaxel alone in the second-line treatment of HER2-amplified advanced gastric cancer in Asian populations: TyTAN--a randomized, phase III study, J Clin Oncol., 32, 2039, 10.1200/JCO.2013.53.6136 Thuss-Patience, 2017, Trastuzumab emtansine versus taxane use for previously treated HER2-positive locally advanced or metastatic gastric or gastro-oesophageal junction adenocarcinoma (GATSBY): an international randomised, open-label, adaptive, phase 2/3 study, Lancet Oncol., 18, 640, 10.1016/S1470-2045(17)30111-0 Tabernero, 2018, Pertuzumab plus trastuzumab and chemotherapy for HER2-positive metastatic gastric or gastro-oesophageal junction cancer (JACOB): final analysis of a double-blind, randomised, placebo-controlled phase 3 study, Lancet Oncol., 19, 1372, 10.1016/S1470-2045(18)30481-9 Shitara, 2020, DESTINY-Gastric01 Investigators. Trastuzumab Deruxtecan in Previously Treated HER2-Positive Gastric Cancer, N Engl J Med, 382, 2419, 10.1056/NEJMoa2004413 Van Cutsem, 2021, Annals of Oncology., 32, S1283 Chaganty, 2018, Trastuzumab upregulates PD-L1 as a potential mechanism of trastuzumab resistance through engagement of immune effector cells and stimulation of IFN(secretion, Cancer Lett., 430, 47, 10.1016/j.canlet.2018.05.009 Loi, 2019, International Breast Cancer Study Group and the Breast International Group. Pembrolizumab plus trastuzumab in trastuzumab-resistant, advanced, HER2-positive breast cancer (PANACEA): a single-arm, multicentre, phase 1b-2 trial, Lancet Oncol., 20, 371, 10.1016/S1470-2045(18)30812-X Janjigian, 2020, First-line pembrolizumab and trastuzumab in HER2-positive oesophageal, gastric, or gastro-oesophageal junction cancer: an open-label, single-arm, phase 2 trial, Lancet Oncol., 21, 821, 10.1016/S1470-2045(20)30169-8 Janjigian, 2021, on behalf of the KEYNOTE-811 investigators. Pembrolizumab plus trastuzumab and chemotherapy for HER2+ metastatic gastric or gastroesophageal junction cancer: Initial findings of the global phase 3 KEYNOTE-811 study, J Clin Oncol., 39 Catenacci, 2020, CP-MGAH22-5 Study Group. Margetuximab plus pembrolizumab in patients with previously treated. HER2-positive gastro-oesophageal adenocarcinoma (CP-MGAH22-05): a single-arm, phase 1b-2 trial, Lancet Oncol., 21, 1066, 10.1016/S1470-2045(20)30326-0 Fuchs, 2018, Safety and Efficacy of Pembrolizumab Monotherapy in Patients With Previously Treated Advanced Gastric and Gastroesophageal Junction Cancer: Phase 2 Clinical KEYNOTE-059 Trial, JAMA Oncol., 4, e180013, 10.1001/jamaoncol.2018.0013 Chen, 2020, A phase 3 study of nivolumab in previously treated advanced gastric or gastroesophageal junction cancer (ATTRACTION-2): 2-year update data, Gastric Cancer., 23, 510, 10.1007/s10120-019-01034-7 Janjigian, 2021, First-line nivolumab plus chemotherapy versus chemotherapy alone for advanced gastric, gastro-oesophageal junction, and oesophageal adenocarcinoma (CheckMate 649): a randomised, open-label, phase 3 trial, Lancet., 398, 27, 10.1016/S0140-6736(21)00797-2 Janjigian, 2021, Nivolumab (NIVO) plus chemotherapy (Chemo) or ipilimumab (IPI) vs chemo as first-line (1L) treatment for advanced gastric cancer/gastroesophageal junction cancer/esophageal adenocarcinoma (GC/GEJC/EAC): CheckMate 649 study, Annals of Oncology., 32, S1283 Marabelle, 2020, Efficacy of Pembrolizumab in Patients With Noncolorectal High Microsatellite Instability/Mismatch Repair-Deficient Cancer: Results From the Phase II KEYNOTE-158 Study, J Clin Oncol., 38, 1, 10.1200/JCO.19.02105 Sun, 2021, KEYNOTE-590 Investigators. Pembrolizumab plus chemotherapy versus chemotherapy alone for first-line treatment of advanced oesophageal cancer (KEYNOTE-590): a randomised, placebo-controlled, phase 3 study, Lancet, 398, 759, 10.1016/S0140-6736(21)01234-4 Smyth, 2021, Checkpoint inhibitors for gastroesophageal cancers: dissecting heterogeneity to better understand their role in first-line and adjuvant therapy, Ann Oncol., 32, 590, 10.1016/j.annonc.2021.02.004 Sahin, 2008, Claudin-18 splice variant 2 is a pan-cancer target suitable for therapeutic antibody development, Clin Cancer Res., 14, 7624, 10.1158/1078-0432.CCR-08-1547 Türeci, 2019, A multicentre, phase IIa study of zolbetuximab as a single agent in patients with recurrent or refractory advanced adenocarcinoma of the stomach or lower oesophagus: the MONO study, Ann Oncol., 30, 1487, 10.1093/annonc/mdz199 Sahin, 2021, FAST: a randomised phase II study of zolbetuximab (IMAB362) plus EOX versus EOX alone for first-line treatment of advanced CLDN18.2-positive gastric and gastro-oesophageal adenocarcinoma, Ann Oncol., 32, 609, 10.1016/j.annonc.2021.02.005 Qi, 2021, CLDN 18.2-targeted CAR-T cell therapy in patients with cancers of the digestive system, Annals of Oncology., 32, S1040, 10.1016/j.annonc.2021.08.1481